Medexus Pharmaceuticals (TSE:MDP) Price Target Raised to C$6.00

Medexus Pharmaceuticals (TSE:MDP) had its target price upped by Stifel Nicolaus from C$4.50 to C$6.00 in a research note published on Thursday morning,BayStreet.CA reports.

Other equities research analysts have also recently issued reports about the company. Ventum Cap Mkts raised Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective on the stock in a research note on Wednesday, January 8th. Finally, Leede Financial upgraded Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd. Two analysts have rated the stock with a buy rating and five have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Strong Buy” and an average target price of C$6.13.

Medexus Pharmaceuticals Stock Performance

MDP stock opened at C$3.99 on Thursday. The company has a market capitalization of C$97.87 million, a PE ratio of 79.80 and a beta of 1.96. The company’s fifty day moving average price is C$3.41 and its 200-day moving average price is C$2.77. Medexus Pharmaceuticals has a one year low of C$1.47 and a one year high of C$5.56.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.